NDC 70004-303
This exact product or package identity exists in FDA auxiliary data but is not present in the current primary NDC product table. The package identity is preserved; status rows are reported source observations, not medical conclusions.
- Requested NDC
- 70004-303
- Product root
- 70004-303
- Identity scope
- Product
- Primary current NDC product row
- Not present
NDC auxiliary status#
These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.
| Dataset | Scope | Product NDC | Package NDC | Code | Status | Reporting period | Source date |
|---|---|---|---|---|---|---|---|
| compounder | package | 70004-303 | 70004-303-30 | COMPOUNDER | Outsourcing facility compounded drug report | 2023-1 | 2026-10-15 |
| compounder | package | 70004-303 | 70004-303-16 | COMPOUNDER | Outsourcing facility compounded drug report | 2023-1 | 2026-10-15 |
| compounder | package | 70004-303 | 70004-303-17 | COMPOUNDER | Outsourcing facility compounded drug report | 2023-1 | 2026-10-15 |
| compounder | package | 70004-303 | 70004-303-63 | COMPOUNDER | Outsourcing facility compounded drug report | 2023-1 | 2026-10-15 |
| compounder | package | 70004-303 | 70004-303-62 | COMPOUNDER | Outsourcing facility compounded drug report | 2023-1 | 2026-10-15 |
| compounder | package | 70004-303 | 70004-303-21 | COMPOUNDER | Outsourcing facility compounded drug report | 2023-1 | 2026-10-15 |
| compounder | package | 70004-303 | 70004-303-21 | COMPOUNDER | Outsourcing facility compounded drug report | 2022-2 | 2026-10-15 |
| compounder | package | 70004-303 | 70004-303-17 | COMPOUNDER | Outsourcing facility compounded drug report | 2022-2 | 2026-10-15 |
| compounder | package | 70004-303 | 70004-303-16 | COMPOUNDER | Outsourcing facility compounded drug report | 2022-2 | 2026-10-15 |
| compounder | package | 70004-303 | 70004-303-17 | COMPOUNDER | Outsourcing facility compounded drug report | 2021-2 | 2026-10-15 |
| compounder | package | 70004-303 | 70004-303-21 | COMPOUNDER | Outsourcing facility compounded drug report | 2021-2 | 2026-10-15 |
| compounder | package | 70004-303 | 70004-303-16 | COMPOUNDER | Outsourcing facility compounded drug report | 2021-2 | 2026-10-15 |
| compounder | package | 70004-303 | 70004-303-27 | COMPOUNDER | Outsourcing facility compounded drug report | 2020-2 | 2026-10-15 |
| compounder | package | 70004-303 | 70004-303-16 | COMPOUNDER | Outsourcing facility compounded drug report | 2020-2 | 2026-10-15 |
| compounder | package | 70004-303 | 70004-303-30 | COMPOUNDER | Outsourcing facility compounded drug report | 2020-2 | 2026-10-15 |
| compounder | package | 70004-303 | 70004-303-22 | COMPOUNDER | Outsourcing facility compounded drug report | 2020-2 | 2026-10-15 |
| compounder | package | 70004-303 | 70004-303-62 | COMPOUNDER | Outsourcing facility compounded drug report | 2020-2 | 2026-10-15 |
| compounder | package | 70004-303 | 70004-303-17 | COMPOUNDER | Outsourcing facility compounded drug report | 2020-2 | 2026-10-15 |
| compounder | package | 70004-303 | 70004-303-21 | COMPOUNDER | Outsourcing facility compounded drug report | 2020-2 | 2026-10-15 |
| compounder | package | 70004-303 | 70004-303-16 | COMPOUNDER | Outsourcing facility compounded drug report | 2020-1 | 2026-10-15 |
| compounder | package | 70004-303 | 70004-303-17 | COMPOUNDER | Outsourcing facility compounded drug report | 2020-1 | 2026-10-15 |
| compounder | package | 70004-303 | 70004-303-22 | COMPOUNDER | Outsourcing facility compounded drug report | 2020-1 | 2026-10-15 |
| compounder | package | 70004-303 | 70004-303-21 | COMPOUNDER | Outsourcing facility compounded drug report | 2020-1 | 2026-10-15 |
| compounder | package | 70004-303 | 70004-303-16 | COMPOUNDER | Outsourcing facility compounded drug report | 2019-2 | 2026-10-15 |
| compounder | package | 70004-303 | 70004-303-22 | COMPOUNDER | Outsourcing facility compounded drug report | 2019-2 | 2026-10-15 |
| compounder | package | 70004-303 | 70004-303-21 | COMPOUNDER | Outsourcing facility compounded drug report | 2019-2 | 2026-10-15 |
| compounder | package | 70004-303 | 70004-303-17 | COMPOUNDER | Outsourcing facility compounded drug report | 2019-2 | 2026-10-15 |
| compounder | package | 70004-303 | 70004-303-17 | COMPOUNDER | Outsourcing facility compounded drug report | 2019-1 | 2026-10-15 |
| compounder | package | 70004-303 | 70004-303-16 | COMPOUNDER | Outsourcing facility compounded drug report | 2019-1 | 2026-10-15 |
| compounder | package | 70004-303 | 70004-303-22 | COMPOUNDER | Outsourcing facility compounded drug report | 2019-1 | 2026-10-15 |
| compounder | package | 70004-303 | 70004-303-21 | COMPOUNDER | Outsourcing facility compounded drug report | 2019-1 | 2026-10-15 |
Observed NDC auxiliary status history#
This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.
| Captured / source date | Package NDC | Reporting period | Snapshot | Source SHA-256 |
|---|---|---|---|---|
| 2025-08-27 00:00 UTC · source 2025-08-20 | 70004-303-63 | 2023-1 | af8e9b524e63… | ca326a94a5e9… |
| 2025-08-27 00:00 UTC · source 2025-08-20 | 70004-303-17 | 2023-1 | af8e9b524e63… | ca326a94a5e9… |
| 2025-08-27 00:00 UTC · source 2025-08-20 | 70004-303-21 | 2023-1 | af8e9b524e63… | ca326a94a5e9… |
| 2025-08-27 00:00 UTC · source 2025-08-20 | 70004-303-30 | 2023-1 | af8e9b524e63… | ca326a94a5e9… |
| 2025-08-27 00:00 UTC · source 2025-08-20 | 70004-303-62 | 2023-1 | af8e9b524e63… | ca326a94a5e9… |
| 2025-08-27 00:00 UTC · source 2025-08-20 | 70004-303-16 | 2023-1 | af8e9b524e63… | ca326a94a5e9… |
| 2025-08-27 00:00 UTC · source 2025-08-20 | 70004-303-16 | 2022-2 | af8e9b524e63… | ca326a94a5e9… |
| 2025-08-27 00:00 UTC · source 2025-08-20 | 70004-303-17 | 2022-2 | af8e9b524e63… | ca326a94a5e9… |
| 2025-08-27 00:00 UTC · source 2025-08-20 | 70004-303-21 | 2022-2 | af8e9b524e63… | ca326a94a5e9… |
| 2025-08-27 00:00 UTC · source 2025-08-20 | 70004-303-21 | 2021-2 | af8e9b524e63… | ca326a94a5e9… |
| 2025-08-27 00:00 UTC · source 2025-08-20 | 70004-303-16 | 2021-2 | af8e9b524e63… | ca326a94a5e9… |
| 2025-08-27 00:00 UTC · source 2025-08-20 | 70004-303-17 | 2021-2 | af8e9b524e63… | ca326a94a5e9… |
| 2025-08-27 00:00 UTC · source 2025-08-20 | 70004-303-17 | 2020-2 | af8e9b524e63… | ca326a94a5e9… |
| 2025-08-27 00:00 UTC · source 2025-08-20 | 70004-303-30 | 2020-2 | af8e9b524e63… | ca326a94a5e9… |
| 2025-08-27 00:00 UTC · source 2025-08-20 | 70004-303-21 | 2020-2 | af8e9b524e63… | ca326a94a5e9… |
| 2025-08-27 00:00 UTC · source 2025-08-20 | 70004-303-62 | 2020-2 | af8e9b524e63… | ca326a94a5e9… |
| 2025-08-27 00:00 UTC · source 2025-08-20 | 70004-303-22 | 2020-2 | af8e9b524e63… | ca326a94a5e9… |
| 2025-08-27 00:00 UTC · source 2025-08-20 | 70004-303-27 | 2020-2 | af8e9b524e63… | ca326a94a5e9… |
| 2025-08-27 00:00 UTC · source 2025-08-20 | 70004-303-16 | 2020-2 | af8e9b524e63… | ca326a94a5e9… |
| 2025-08-27 00:00 UTC · source 2025-08-20 | 70004-303-16 | 2020-1 | af8e9b524e63… | ca326a94a5e9… |
| 2025-08-27 00:00 UTC · source 2025-08-20 | 70004-303-21 | 2020-1 | af8e9b524e63… | ca326a94a5e9… |
| 2025-08-27 00:00 UTC · source 2025-08-20 | 70004-303-17 | 2020-1 | af8e9b524e63… | ca326a94a5e9… |
| 2025-08-27 00:00 UTC · source 2025-08-20 | 70004-303-22 | 2020-1 | af8e9b524e63… | ca326a94a5e9… |
| 2025-08-27 00:00 UTC · source 2025-08-20 | 70004-303-16 | 2019-2 | af8e9b524e63… | ca326a94a5e9… |
| 2025-08-27 00:00 UTC · source 2025-08-20 | 70004-303-17 | 2019-2 | af8e9b524e63… | ca326a94a5e9… |
| 2025-08-27 00:00 UTC · source 2025-08-20 | 70004-303-22 | 2019-2 | af8e9b524e63… | ca326a94a5e9… |
| 2025-08-27 00:00 UTC · source 2025-08-20 | 70004-303-21 | 2019-2 | af8e9b524e63… | ca326a94a5e9… |
| 2025-08-27 00:00 UTC · source 2025-08-20 | 70004-303-16 | 2019-1 | af8e9b524e63… | ca326a94a5e9… |
| 2025-08-27 00:00 UTC · source 2025-08-20 | 70004-303-22 | 2019-1 | af8e9b524e63… | ca326a94a5e9… |
| 2025-08-27 00:00 UTC · source 2025-08-20 | 70004-303-21 | 2019-1 | af8e9b524e63… | ca326a94a5e9… |
| 2025-08-27 00:00 UTC · source 2025-08-20 | 70004-303-17 | 2019-1 | af8e9b524e63… | ca326a94a5e9… |
| 2025-01-13 04:20 UTC · source 2024-11-20 | 70004-303-21 | 2023-1 | 85f958c8d153… | 997044a9741e… |
| 2025-01-13 04:20 UTC · source 2024-11-20 | 70004-303-63 | 2023-1 | 85f958c8d153… | 997044a9741e… |
| 2025-01-13 04:20 UTC · source 2024-11-20 | 70004-303-17 | 2023-1 | 85f958c8d153… | 997044a9741e… |
| 2025-01-13 04:20 UTC · source 2024-11-20 | 70004-303-16 | 2023-1 | 85f958c8d153… | 997044a9741e… |
| 2025-01-13 04:20 UTC · source 2024-11-20 | 70004-303-30 | 2023-1 | 85f958c8d153… | 997044a9741e… |
| 2025-01-13 04:20 UTC · source 2024-11-20 | 70004-303-62 | 2023-1 | 85f958c8d153… | 997044a9741e… |
| 2025-01-13 04:20 UTC · source 2024-11-20 | 70004-303-17 | 2022-2 | 85f958c8d153… | 997044a9741e… |
| 2025-01-13 04:20 UTC · source 2024-11-20 | 70004-303-16 | 2022-2 | 85f958c8d153… | 997044a9741e… |
| 2025-01-13 04:20 UTC · source 2024-11-20 | 70004-303-21 | 2022-2 | 85f958c8d153… | 997044a9741e… |
| 2022-05-13 07:20 UTC · source 2022-04-19 | 70004-303-16 | 2021-2 | 4694734df12d… | db2bf3a0aaab… |
| 2022-05-13 07:20 UTC · source 2022-04-19 | 70004-303-17 | 2021-2 | 4694734df12d… | db2bf3a0aaab… |
| 2022-05-13 07:20 UTC · source 2022-04-19 | 70004-303-21 | 2021-2 | 4694734df12d… | db2bf3a0aaab… |
Compounder NDC reports#
| Establishment | FEI | Product NDC | Package NDC | Product | Active ingredients | Reporting period | Normalization |
|---|---|---|---|---|---|---|---|
| "SCA Pharmaceuticals, LLC(080545245)" | 70004-303 | 70004-303-16 | Hydromorphone Hydrochloride | 1 mg/1 mL | 2023-1 | valid | |
| "SCA Pharmaceuticals, LLC(080545245)" | 70004-303 | 70004-303-17 | Hydromorphone Hydrochloride | 1 mg/1 mL | 2023-1 | valid | |
| "SCA Pharmaceuticals, LLC(080545245)" | 70004-303 | 70004-303-21 | Hydromorphone Hydrochloride | 1 mg/1 mL | 2023-1 | valid | |
| "SCA Pharmaceuticals, LLC(080545245)" | 70004-303 | 70004-303-30 | Hydromorphone Hydrochloride | 1 mg/1 mL | 2023-1 | valid | |
| "SCA Pharmaceuticals, LLC(080545245)" | 70004-303 | 70004-303-62 | Hydromorphone Hydrochloride | 1 mg/1 mL | 2023-1 | valid | |
| "SCA Pharmaceuticals, LLC(080545245)" | 70004-303 | 70004-303-63 | Hydromorphone Hydrochloride | 1 mg/1 mL | 2023-1 | valid | |
| "SCA Pharmaceuticals, LLC(080545245)" | 70004-303 | 70004-303-16 | Hydromorphone Hydrochloride | 1 mg/1 mL | 2022-2 | valid | |
| "SCA Pharmaceuticals, LLC(080545245)" | 70004-303 | 70004-303-17 | Hydromorphone Hydrochloride | 1 mg/1 mL | 2022-2 | valid | |
| "SCA Pharmaceuticals, LLC(080545245)" | 70004-303 | 70004-303-21 | Hydromorphone Hydrochloride | 1 mg/1 mL | 2022-2 | valid | |
| "SCA Pharmaceuticals, LLC(080545245)" | 70004-303 | 70004-303-16 | Hydromorphone Hydrochloride | 1 mg/1 mL | 2021-2 | valid | |
| "SCA Pharmaceuticals, LLC(080545245)" | 70004-303 | 70004-303-17 | Hydromorphone Hydrochloride | 1 mg/1 mL | 2021-2 | valid | |
| "SCA Pharmaceuticals, LLC(080545245)" | 70004-303 | 70004-303-21 | Hydromorphone Hydrochloride | 1 mg/1 mL | 2021-2 | valid | |
| "SCA Pharmaceuticals, LLC(080545245)" | 70004-303 | 70004-303-16 | Hydromorphone Hydrochloride | 1 mg/1 mL | 2020-2 | valid | |
| "SCA Pharmaceuticals, LLC(080545245)" | 70004-303 | 70004-303-17 | Hydromorphone Hydrochloride | 1 mg/1 mL | 2020-2 | valid | |
| "SCA Pharmaceuticals, LLC(080545245)" | 70004-303 | 70004-303-21 | Hydromorphone Hydrochloride | 1 mg/1 mL | 2020-2 | valid | |
| "SCA Pharmaceuticals, LLC(080545245)" | 70004-303 | 70004-303-22 | Hydromorphone Hydrochloride | 1 mg/1 mL | 2020-2 | valid | |
| "SCA Pharmaceuticals, LLC(080545245)" | 70004-303 | 70004-303-27 | Hydromorphone Hydrochloride | 1 mg/1 mL | 2020-2 | valid | |
| "SCA Pharmaceuticals, LLC(080545245)" | 70004-303 | 70004-303-30 | Hydromorphone Hydrochloride | 1 mg/1 mL | 2020-2 | valid | |
| "SCA Pharmaceuticals, LLC(080545245)" | 70004-303 | 70004-303-62 | Hydromorphone Hydrochloride | 1 mg/1 mL | 2020-2 | valid | |
| "SCA Pharmaceuticals, LLC(080545245)" | 70004-303 | 70004-303-16 | Hydromorphone Hydrochloride | 1 mg/1 mL | 2020-1 | valid | |
| "SCA Pharmaceuticals, LLC(080545245)" | 70004-303 | 70004-303-17 | Hydromorphone Hydrochloride | 1 mg/1 mL | 2020-1 | valid | |
| "SCA Pharmaceuticals, LLC(080545245)" | 70004-303 | 70004-303-21 | Hydromorphone Hydrochloride | 1 mg/1 mL | 2020-1 | valid | |
| "SCA Pharmaceuticals, LLC(080545245)" | 70004-303 | 70004-303-22 | Hydromorphone Hydrochloride | 1 mg/1 mL | 2020-1 | valid | |
| "SCA Pharmaceuticals, LLC(080545245)" | 70004-303 | 70004-303-16 | Hydromorphone Hydrochloride | 1 mg/1 mL | 2019-2 | valid | |
| "SCA Pharmaceuticals, LLC(080545245)" | 70004-303 | 70004-303-17 | Hydromorphone Hydrochloride | 1 mg/1 mL | 2019-2 | valid | |
| "SCA Pharmaceuticals, LLC(080545245)" | 70004-303 | 70004-303-21 | Hydromorphone Hydrochloride | 1 mg/1 mL | 2019-2 | valid | |
| "SCA Pharmaceuticals, LLC(080545245)" | 70004-303 | 70004-303-22 | Hydromorphone Hydrochloride | 1 mg/1 mL | 2019-2 | valid | |
| "SCA Pharmaceuticals, LLC(037559301)" | 70004-303 | 70004-303-16 | Hydromorphone Hydrochloride | 1 mg/1 mL | 2019-1 | valid | |
| "SCA Pharmaceuticals, LLC(037559301)" | 70004-303 | 70004-303-17 | Hydromorphone Hydrochloride | 1 mg/1 mL | 2019-1 | valid | |
| "SCA Pharmaceuticals, LLC(037559301)" | 70004-303 | 70004-303-21 | Hydromorphone Hydrochloride | 1 mg/1 mL | 2019-1 | valid | |
| "SCA Pharmaceuticals, LLC(037559301)" | 70004-303 | 70004-303-22 | Hydromorphone Hydrochloride | 1 mg/1 mL | 2019-1 | valid |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.